Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions

Inclusion Criteria: * Signed informed consent and authorization of use and disclosure of protected health information * Age equal to or greater than 18 years * Diagnosis of macular edema due to central or branch retinal vein occlusion * Foveal thickness of equal to or greater than 250 mm, as assessed by OCT * Best corrected visual acuity score in the study eye of 20/40 to 20/400 inclusive (Snellen equivalents using the ETDRS protocol at a distance of 4 meters). Only one eye will be treated in the study. If both eyes are eligible, the investigator will select the eye to be enrolled. * In the opinion of the investigator, decreased vision in the study eye is due to foveal thickening from vein occlusion and not from other obvious causes of decreased vision Exclusion Criteria: * Scatter laser photocoagulation or macular photocoagulation within 3 months of study entry in the study eye * Intraocular surgery in the study eye within 3 months of study entry * Use of intraocular or periocular injection of steroids in the study eye (e.g., triamcinolone) within 4 months of study entry * Previous use of an anti-VEGF drug within 3 months of study entry * Cataract surgery in the study eye within 3 months of study entry; Yttrium-Aluminum-Garnet (YAG) laser capsulotomy within 1 month of study entry; or any other intraocular surgery within 3 months preceding Day 0. * History of vitreoretinal surgery in the study eye within 3 months of study entry * Uncontrolled glaucoma (defined as intraocular pressure ³30 mm Hg despite treatment with anti-glaucoma medications) * History of cerebral vascular accident, myocardial infarction, transient ischemic attacks within 3 months of study enrollment. * Pregnancy (positive pregnancy test) or lactation * Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch. * Have the presence of active malignancy, including lymphoproliferative disorders. Subjects with a history of fully resolved basal or squamous cell skin cancer may be enrolled. * Any condition that the investigator believes would pose a significant hazard to the subject if investigational therapy were initiated. * History of allergy to humanized antibodies or any component of the ranibizumab formulation * Inability to comply with study or followup procedures * Participation in another simultaneous medical investigation or trial